Undifferentiated Embryonal Sarcoma of the Liver: Evaluation of the Relapse Profile According to the Therapies Administered

Completed

• Conditions: Hepatic Sarcoma

• Registration Number: NCT05640960
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Undifferentiated embryonal sarcoma of the liver is the 3rd most common malignant liver tumor after hepatoblastoma and hepatocellular carcinoma with a peak incidence between 6 and 10 years of age. Historically, it is a tumor treated only by surgery with a poor prognosis. In the last decade, the combination of more intensive chemotherapy and, more randomly, radiotherapy, has significantly improved the survival rate of these patients. Due to its low incidence, there are few series reported in the literature and to date there is no specific treatment protocol for the management of these tumors.

It seems appropriate to review the management of these tumors in France in order to discuss the best therapeutic strategy.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-11
• Primary Completion: 2021-11-11
• Study Completion: 2021-12-31
• Study First Submitted: 2022-11-28
• Study First Submitted QC: 2022-11-28
• Study First Posted: 2022-12-07
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-07
• Last Update Posted: 2023-12-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Describe the relapse profile of children with undifferentiated hepatic sarcoma according to the therapies received	3 years after treatment	the primary endpoint is event-free survival (progression, death, relapse) at 3 years.

Trial Locations

Locations (1)

Service Pédiatrie Onco-hématologie - Pédiatrie III - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France